Detalhe da pesquisa
1.
RAS/RAFlandscape in monoclonal plasma cell conditions.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643494
2.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Blood
; 141(11): 1308-1315, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375118
3.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Blood
; 139(17): 2666-2672, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35171994
4.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood
; 139(18): 2747-2757, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511184
5.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
Eur J Haematol
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38712850
6.
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Br J Haematol
; 201(6): 1103-1115, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974007
7.
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Blood
; 138(2): 113-121, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827114
8.
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood
; 137(9): 1192-1195, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080624
9.
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica
; 108(5): 1374-1384, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36172814
10.
Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma.
Eur Radiol
; 32(5): 3085-3096, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34842956
11.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
12.
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Blood
; 143(8): 734-737, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096365
13.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
14.
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
N Engl J Med
; 376(14): 1311-1320, 2017 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28379796
15.
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Blood
; 132(24): 2555-2563, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30282798
16.
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Blood
; 132(23): 2456-2464, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249784
17.
Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.
J Am Soc Nephrol
; 30(7): 1206-1219, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31227636
18.
Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma.
Radiology
; 286(2): 560-567, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28985135
19.
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Blood
; 127(21): 2569-74, 2016 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27002117
20.
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.
Blood
; 128(25): 2941-2948, 2016 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27729323